The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Leif Groop

Leif Groop

Principal investigator

Leif Groop

Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease


  • Panu K. Luukkonen
  • Taru Tukiainen
  • Anne Juuti
  • Henna Sammalkorpi
  • P. A. Nidhina Haridas
  • Onni Niemelä
  • Johanna Arola
  • Marju Orho-Melander
  • Antti Hakkarainen
  • Petri T. Kovanen
  • Om Dwivedi
  • Leif Groop
  • Leanne Hodson
  • Amalia Gastaldelli
  • Tuulia Hyötyläinen
  • Matej Orešič
  • Hannele Yki-Järvinen

Summary, in English

Carriers of the hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) gene variant (rs72613567:TA) have a reduced risk of NASH and cirrhosis but not steatosis. We determined its effect on liver histology, lipidome, and transcriptome using ultra performance liquid chromatography-mass spectrometry and RNA-seq. In carriers and noncarriers of the gene variant, we also measured pathways of hepatic fatty acids (de novo lipogenesis [DNL] and adipose tissue lipolysis [ATL] using 2H2O and 2H-glycerol) and insulin sensitivity using 3H-glucose and euglycemic-hyperinsulinemic clamp) and plasma cytokines. Carriers and noncarriers had similar age, sex and BMI. Fibrosis was significantly less frequent while phospholipids, but not other lipids, were enriched in the liver in carriers compared with noncarriers. Expression of 274 genes was altered in carriers compared with noncarriers, consisting predominantly of downregulated inflammation-related gene sets. Plasma IL-6 concentrations were lower, but DNL, ATL and hepatic insulin sensitivity were similar between the groups. In conclusion, carriers of the HSD17B13 variant have decreased fibrosis and expression of inflammation-related genes but increased phospholipids in the liver. These changes are not secondary to steatosis, DNL, ATL, or hepatic insulin sensitivity. The increase in phospholipids and decrease in fibrosis are opposite to features of choline-deficient models of liver disease and suggest HSD17B13 as an attractive therapeutic target.


  • Diabetes - Cardiovascular Disease
  • EXODIAB: Excellence of Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health
  • Genomics, Diabetes and Endocrinology

Publishing year





JCI Insight





Document type

Journal article


The American Society for Clinical Investigation


  • Endocrinology and Diabetes
  • Medical Genetics



Research group

  • Diabetes - Cardiovascular Disease
  • Genomics, Diabetes and Endocrinology


  • ISSN: 2379-3708